ArticleMolecules (Basel, Switzerland)2020
Modulating the Properties of Fe(III) Macrocyclic MRI Contrast Agents by Appending Sulfonate or Hydroxyl Groups.
Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 37 citations in OpenAlex.
- Inner- and Second-Sphere Interactions of Co(II) and Fe(II) Parashift Agents with Lactate, Trifluorolactate, and Fluoride.Inorganic chemistry · 2026Article
- [Fe-EOB-tCDTA] generates strong contrast in the blood but not in the liver, despite inhibiting cellular [Gd-EOB-DTPA]European radiology experimental · 2026Article
- Iron(III)-Quercetin Complex: In Vivo Acute Toxicity and Biodistribution of Novel MRI Agent.International journal of nanomedicine · 2025Article
- Zn(II)-Responsive MRI Probe Based on an Fe(III) Macrocyclic Complex.Inorganic chemistry · 2024Article
- Self-Assembled Iron(III) Coordination Cage as an MRI-Active Carrier for a Gold(I) Drug.Bioconjugate chemistry · 2024Article
- Macrocyclic complexes of Fe(III) with mixed hydroxypropyl and phenolate or amide pendants as TDalton transactions (Cambridge, England : 2003) · 2024Article
- Endeavor toward Redox-Responsive Transition Metal Contrast Agents Based on the Cross-Bridge Cyclam Platform.Inorganic chemistry · 2024Article
- Design and synthesis of chiral DOTA-based MRI contrast agents with remarkable relaxivities.Communications chemistry · 2023Article
- Fe(III)Inorganic chemistry · 2023Article
- Liposomal MRI probes containing encapsulated or amphiphilic Fe(III) coordination complexes.Biomaterials science · 2023Article
- An Fe complex forChemical science · 2023Article
- Metal-Assembled Collagen Peptide Microflorettes as Magnetic Resonance Imaging Agents.Molecules (Basel, Switzerland) · 2023Article
- Bioimaging agents based on redox-active transition metal complexes.Chemical science · 2022Review
- Low-Molecular-Weight Fe(III) Complexes for MRI Contrast Agents.Molecules (Basel, Switzerland) · 2022Review
- Metal-Organic Polyhedron with Four Fe(III) Centers Producing Enhanced TInorganic chemistry · 2022Article
- Enzyme Control Over Ferric Iron Magnetostructural Properties.Angewandte Chemie (International ed. in English) · 2022Article
- Comparison of phosphonate, hydroxypropyl and carboxylate pendants in Fe(III) macrocyclic complexes as MRI contrast agents.Journal of inorganic biochemistry · 2021Article
- Liposomal Fe(III) Macrocyclic Complexes with Hydroxypropyl Pendants as MRI Probes.ACS applied bio materials · 2021Article
- Defining the conditions for the development of the emerging class of FeChemical science · 2021Article
- Dinuclear Fe(III) Hydroxypropyl-Appended Macrocyclic Complexes as MRI Probes.Inorganic chemistry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Complexes of Fe(III) that contain a triazacyclononane (TACN) macrocycle, two pendant hydroxyl groups, and a third ancillary pendant show promise as MRI contrast agents. The ancillary group plays an important role in tuning the solution relaxivity of the Fe(III) complex and leads to large changes in MRI contrast enhancement in mice. Two new Fe(III) complexes, one with a third coordinating hydroxypropyl pendant, Fe(L2), and one with an anionic non-coordinating sulfonate group, Fe(L1)(OH
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.